Piramal Pharma Limited

Piramal Pharma Limited

Piramal Pharma Limited has announced its Q1 FY27 results, with a 17% revenue growth, 72% EBITDA growth, and 12.5% EBITDA margin expansion. The company's CDMO business delivered broad-based growth, while its Complex Hospital Generics and Consumer Healthcare businesses maintained leadership positions in their respective markets.

Piramal Pharma Limited

Piramal Pharma Limited announced its standalone and consolidated results for Q1 FY27, with a 17% revenue growth, 72% EBITDA increase, and 12.5% EBITDA margin expansion.

Piramal Pharma Limited

Piramal Pharma Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 1,124.95 crores and net profit after tax at Rs. 113.48 crores.

Piramal Pharma Limited

Piramal Pharma Limited has granted 56,36,436 stock options to employees under the Employee Stock Option and Incentive Plan 2022. The options have been granted at an exercise price of Rs.10/- per option and will be exercisable within 5 years commencing from the date of vesting of each tranche.

Piramal Pharma Limited

Piramal Pharma Limited has temporarily suspended operations at its manufacturing facilities in Ahmedabad, Gujarat, due to heavy rainfall and flooding. The company has initiated actions to assess the situation and resume operations safely. The affected facilities account for less than 3% of the company's consolidated revenues.

Piramal Pharma Limited

Piramal Pharma Limited has informed the Exchange about the schedule of a conference call with investors/analysts to discuss its Q1 FY2027 Results on 30th July 2026.

Piramal Pharma Limited

Piramal Pharma Limited has successfully closed a US FDA inspection at its manufacturing facility in Sellersville, USA, with the issuance of an Establishment Inspection Report (EIR).

Piramal Pharma Limited

Piramal Pharma Limited has published a newspaper advertisement for the dispatch of notice of the 6th Annual General Meeting (AGM) and e-voting information, as per Regulation 30 of the SEBI Listing Regulations. The AGM is scheduled to be held on July 30, 2026, through video conference or other audio-visual means. The company also requests shareholders to update their Know Your Customer (KYC) details and claim unpaid dividends to prevent transfer to the Investor Education and Protection Fund (IEPF).

Piramal Pharma Limited

Piramal Pharma Limited has submitted its Business Responsibility & Sustainability Report for the financial year 2025-26, as per the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Piramal Pharma Limited

Piramal Pharma Limited has announced its 6th Annual General Meeting (AGM) and Annual Report for the financial year 2025-26, which will be held on July 30, 2026, through video conferencing.

Piramal Pharma Limited

Piramal Pharma Limited's promoter, Ajay G. Piramal, has submitted a declaration under SEBI Takeover Regulations stating that the promoter group has not made any encumbrance on the company's shares during the financial year 2025-2026.

Piramal Pharma Limited

Piramal Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Piramal Pharma Limited

Piramal Pharma Limited received a query from the Stock Exchanges regarding a news article about a 10% surge in its share price. The company clarified that the news article does not contain any material information requiring disclosure under Regulation 30 of SEBI Listing Regulations. It further stated that all necessary information is already in the public domain and that the share price movement appears to be driven by market dynamics, with no specific undisclosed reason known to the company.

Piramal Pharma Limited

The National Stock Exchange (NSE) has formally requested Piramal Pharma Limited to provide clarification regarding a recent news article titled 'Piramal Pharma Share Price Spikes Over 10% - What Is Driving The Rally?'. The company's official response to this inquiry is still pending. This request is a standard compliance procedure aimed at ensuring market transparency and verifying the information contributing to significant stock price movements.

Piramal Pharma Limited

Piramal Pharma Limited announced the publication of newspaper advertisements informing shareholders about its upcoming 6th Annual General Meeting (AGM). The AGM is scheduled for Thursday, July 30, 2026, at 3:00 p.m. (IST) and will be conducted virtually via Video Conferencing or Other Audio Visual Means. Notices were published in Business Standard (English) and Mumbai Lakshadweep (Marathi), in compliance with SEBI Listing Regulations. This announcement formally notifies investors about the meeting where key company matters will be discussed, enabling them to prepare for participation.